Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 5
2011 5
2012 2
2013 3
2014 5
2015 5
2016 6
2017 4
2018 2
2019 1
2020 2
2022 4
2023 3
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Update on Pregnancy Following Breast Cancer Diagnosis and Treatment.
Perachino M, Poggio F, Arecco L, Blondeaux E, Spinaci S, Marrocco C, Levaggi A, Lambertini M. Perachino M, et al. Among authors: levaggi a. Cancer J. 2022 May-Jun 01;28(3):176-182. doi: 10.1097/PPO.0000000000000599. Cancer J. 2022. PMID: 35594464 Review.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L; Gruppo Italiano Mammella Investigators. Del Mastro L, et al. Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10. Lancet Oncol. 2022. PMID: 36370716 Clinical Trial.
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Delle Piane C, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S. Miglietta F, et al. Among authors: levaggi a. Breast. 2022 Dec;66:293-304. doi: 10.1016/j.breast.2022.10.014. Epub 2022 Oct 29. Breast. 2022. PMID: 36379199 Free PMC article. Review.
Approaches to Fertility Preservation for Young Women With Breast Cancer.
Razeti MG, Soldato D, Arecco L, Levaggi A, Puglisi S, Solinas C, Agostinetto E, Spinaci S, Lapuchesky L, Genova C, Massarotti C, Lambertini M. Razeti MG, et al. Among authors: levaggi a. Clin Breast Cancer. 2023 Apr;23(3):241-248. doi: 10.1016/j.clbc.2023.01.006. Epub 2023 Jan 14. Clin Breast Cancer. 2023. PMID: 36710145 Review.
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.
Poggio F, Ceppi M, Lambertini M, Bruzzi P, Ugolini D, Bighin C, Levaggi A, Giraudi S, D'Alonzo A, Vaglica M, Blondeaux E, Sertoli MR, Pronzato P, Del Mastro L. Poggio F, et al. Among authors: levaggi a. Breast. 2017 Jun;33:104-108. doi: 10.1016/j.breast.2017.03.011. Epub 2017 Mar 27. Breast. 2017. PMID: 28360014 Review.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups. Lambertini M, et al. Among authors: levaggi a. Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10. Eur J Cancer. 2017. PMID: 27951450 Clinical Trial.
42 results